GEMoaB Monoclonals GmbH

General information
GEMoaB Monoclonals GmbH
Tatzberg 47
01307 Dresden, Saxony
Germany

Contact person: Michael Pehl, CEO
Company main phone: +49 (351) 44664500
Website:  www.gemoab.com
Year founded:2011
Source of foundation:Independent foundation
Corporate description / mission:
GEMoaB GmbH is a privately-owned, limited liability biopharmaceutical company based in Dresden, Germany. The company discovers, develops, manufactures, and commercializes next-generation immunotherapies for the treatment of cancer patients with a high unmet medical need.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector:
  • Biotechnology - Therapeutics and Diagnostics
Subsector:
  • Antibodies
  • Immunotherapy
  • Other
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • R&D
  • Other
Customer segments:
  • Other
  • Hospitals
  • Large biotech & big pharma
  • Physicians / doctors
Summary Products / Services / Technologies
Description of products:
GEM333
GEM3PSCA
UniCAR-T-PSMA
UniCAR-T 3, etc.
Technology used:
UniCAR/RevCAR Platforms
ATAC Platform
X